Interleukin-10 Inhibits Bone Resorption: A Potential Therapeutic Strategy in Periodontitis and Other Bone Loss Diseases
Open Access
- 1 January 2014
- journal article
- review article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2014, 1-5
- https://doi.org/10.1155/2014/284836
Abstract
Periodontitis and other bone loss diseases, decreasing bone volume and strength, have a significant impact on millions of people with the risk of tooth loss and bone fracture. The integrity and strength of bone are maintained through the balance between bone resorption and bone formation by osteoclasts and osteoblasts, respectively, so the loss of bone results from the disruption of such balance due to increased resorption or/and decreased formation of bone. The goal of therapies for diseases of bone loss is to reduce bone loss, improve bone formation, and then keep healthy bone density. Current therapies have mostly relied on long-term medication, exercise, anti-inflammatory therapies, and changing of the life style. However there are some limitations for some patients in the effective treatments for bone loss diseases because of the complexity of bone loss. Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine, and recent studies have indicated that IL-10 can contribute to the maintenance of bone mass through inhibition of osteoclastic bone resorption and regulation of osteoblastic bone formation. This paper will provide a brief overview of the role of IL-10 in bone loss diseases and discuss the possibility of IL-10 adoption in therapy of bone loss diseases therapy.Keywords
Funding Information
- Key Project of Science and Technology Bureau of Jiangsu Province (BL2013002, 201303051)
This publication has 69 references indexed in Scilit:
- IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cellsBMC Cancer, 2013
- Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcomeBMC Cancer, 2013
- Metastasis and bone loss: Advancing treatment and preventionCancer Treatment Reviews, 2010
- Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to PreventionRheumatic Disease Clinics of North America, 2010
- Molecular biology of bone remodeling: Implications for new therapeutic targets for osteoporosisMaturitas, 2010
- Immune Response and Alveolar Bone Resorption in a Mouse Model ofTreponema denticolaInfectionInfection and Immunity, 2009
- Interleukin‐10: new perspectives on an old cytokineImmunological Reviews, 2008
- Association of interleukin‐6 and interleukin‐10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody statusArthritis & Rheumatism, 2007
- Interleukin-10 Inhibits Gram-Negative-Microbe-Specific Human Receptor Activator of NF-κB Ligand-Positive CD4 + -Th1-Cell- Associated Alveolar Bone Loss In VivoInfection and Immunity, 2006
- Osteoclast differentiation and activationNature, 2003